Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Any hopes of differentiation could come down to side effects.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
